Preclinical testing and results of Protearin™ make a strong case to use clusterin as a biological drug to prevent or treat not only dry eye but also other corneal disorders involving damage to the ocular surface barrier.  

Studies conducted at the University of Southern California in a preclinical model of dry eye demonstrated the remarkable potential for Protearin™ to protect the ocular surface barrier and to improve preexisting barrier disruption - potentially positioning Protearin™ as a first of its kind platform therapy for multiple conditions.

No drugs are currently on the market to address ocular surface barrier disruption.